Biocon reported a decline of 95% yoy in net profit, 15% in operating revenue

Biocon The net profit reported in June ended in June ended in the first quarter recorded a decline of 95% year-on-year. However, the company has claimed that the profit has been increased by 65% after tax on a similar basis for this way, after adjusting for the benefit of a one -time division, a year ago, in the same trimester, from the sale of metabolic, oncology and important care portfolio to the sale of its branded formulations from the sale of its branded formulations from the sale of its branded formulas (BFI) business Eris lifestyle,

The company said in a statement that the company’s operating revenue for Q1Fy26 increased from 15% to Rs 3,942 crore, while the Ebitda was at Rs 829 crore, such as 19% with 19% Ebitda margin with Ebitda margin of 21%, the company said in a statement.

“Recently QIP has strengthened our balance sheet and enables us to increase its ownership in biocon biologics by facilitating the exit of structured equity investors, which aligns the capital structure with long-term strategic priorities,” Kiran Majumdar-Shaw, Chairperson, said by the Biocon Group.

“With the speed of execution in all businesses and extended capacity through acquisition in the US by Sinnine and Biocon Jenrich, we are well deployed to manufacture fiscal year 26 and beyond,” Shaw said.

BIOCON concludes its first equity funds since 2004 IPO, raised Rs 4,500 crore through one Qualified institutions appointment (QIP) in June. The company said the funds would be used to increase the holding of Biocon in Biocon Biologics and to exit private equity investors in Biocon Biologics.

The company’s API and generic formulation business reported an increase of 6% in revenue by Rs 697 crore from operations. “The trimester increase was mainly operated by revenue from the recent drug product launch, including Liraglutide in the European Union and Dastinib and Lenalidomide in the United States, supporting high amounts in our API business,” Sidd to launching new products, including commercialization of lirglutide in major strategic markets, ”said.

Biocon Biologics posted 18% year-on-year revenue growth, which was inspired by strong demand in major markets.

Due to operation, the company’s CRDMO business Syngene’s revenue increased by 11% year-on-year to Rs 875 crore and Ebitda was at Rs 224 crore, with a 19% increase.

The CEO and Managing Director, Peter Bains said, “Constant growth in research services was conducted, as pilot programs had transfusted in long -term contracts.” Singin International,